Should you buy Ocugen stock now?
No, the technical signal for Ocugen is currently SELL. Ocugen trades at $1.27 as of 8/6/2026. The overall technical signal is: Strong Sell. The technical analysis shows the following: MACD is negative (bearish trend) at -0.039 with falling momentum (signal: -0.038); RSI is at 45.9 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $12.17 points to 858.3% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Ocugen stock?
The average analyst price target for Ocugen is $12.17. The current price is $1.27, which gives an upside of 858.3%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $10.95 and $13.39.
Is Ocugen a dividend stock?
No, Ocugen does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Ocugen stock?
Ocugen is rated as a stock with extreme risk. the annual standard deviation is 80.0%, which classifies the stock as extreme risk.
Is Ocugen overvalued?
No, Ocugen is considered undervalued based on the analyst price target (858.3% upside). Ocugen has the following valuation ratios: a P/S ratio of 99.5, a P/B ratio of 72.9. The analyst price target suggests that the stock is undervalued by 858.3%.
Is Ocugen overbought?
No, Ocugen is not overbought. RSI is at 45.9 (neutral zone). The technical indicators show: RSI is at 45.9 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 3.6% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Ocugen earnings report?
Ocugen reports earnings TODAY, August 6, 2026! The stock currently trades at $1.27. Watch how the price reacts after the release.
Is Ocugen shorted?
Yes, Ocugen is shorted with 29.9% of the free float sold short. This is an extremely high level of short selling, which points to great skepticism among institutional investors. The risk of a short squeeze on positive news or earnings is very high. Data is updated daily based on official filings with the SEC.
Are insiders buying Ocugen stock?
Yes, insiders are net buyers of Ocugen – they are buying more shares than they are selling. Over the last 3 months, insiders have made 1 purchases and 0 sales. On a net basis, 25,830 $ worth of shares were bought. Across the last 20 reported transactions, the split is 7 purchases and 13 sales, with a net 600,891 $ sold. Active buyers include Johnson-Greene Treerita Essalima, Zhang Junge, Prabhavathi Fernandes and others. Insider buying is generally seen as a positive signal, because management is putting its own money into the company.
Is Ocugen a good stock?
Based on our total score, Ocugen is rated as a disastrous stock with a total score of 7 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 2/100, Quality: 6/100, Momentum: 14/100. In addition: analysts see 858.3% upside to the price target; technical signal: Strong Sell. Whether Ocugen is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Ocugen stock?
The outlook for Ocugen based on current data: the average analyst price target is $12.17 (+858.3%); the stock is in a downtrend (below SMA50 and SMA200); the next earnings report is due on 8/6/2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Ocugen stock falling?
Ocugen is falling right now. The technical indicators show: the price is 3.6% below the 20-day average; MACD is negative with falling momentum (bearish signal); short interest is 29.9% (high – many are betting on a decline); insiders have mostly been buying the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Ocugen go?
The average analyst price target for Ocugen is $12.17, which corresponds to a potential gain of 858.3% from the current price of $1.27. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Ocugen fall?
We lack enough history to give a specific floor for Ocugen. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Ocugen do?
Ocugen er et biotekselskab, som udvikler genterapi for at kurere blindhed. De fokuserer primært på øjensygdomme, hvor de laver behandlinger, der skal genoprette synet.
Deres pipeline rummer flere kandidater, blandt andet OCU400, som er en genterapi mod forskellige arvelige ne... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Ocugen as an investment.
Did Ocugen raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Ocugen. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Ocugen making money or losing money?
We have no current profitability data for Ocugen. See the latest report in the earnings history above.
Can Ocugen go bankrupt?
The bankruptcy risk of Ocugen is rated as elevated. Altman Z2 (a model for assessing financial distress) is -30.11 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 2 — which is weak. Debt relative to equity is 178% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Ocugen have a lot of debt?
Yes, Ocugen has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 178%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
